Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > ADC

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 26, 2022 11:24am

126 Views

Post# 34851108

RE:ADC

It's seems like such an exciting breakthrough in breast cancer. A whole new cohort of patients that can be treated with her2 therapy. Almost a qualitative difference, not just quantative. It speaks to targeted therapy as really cutting edge stuff, you don't always need the mind-boggling science.

scarlet1967 wrote:

“The FDA has granted a priority review to AZ and Daiichi’s bid to expand Enhertu into previously treated HER2-low breast cancer, the two companies said Monday.

Further, the agency is smoothing the process with two more expedited review programs. It’s reviewing the submission under the Real-Time Oncology Review pathway, which allows for early evaluation of data before completion of an application package. And it's putting the application into Project Orbis, which means foreign regulators can partake in the review.”

A bit premature and might not totally related to THTX’s PDC but one can see the snow ball effect once the process seriously starts.

So possibly if there is high enough level of affinity between TH19series and sortilin the drug can be potentially treating earlier stages of cancers thus much larger targeted patients which can be on the drug for longer periods of time. Another factor to consider is FDA’s willingness to review submission based on “Real-Time Oncology Review pathway” and the project Orbis, description below.

I thought as some of our insiders are doing what they do best which is sabotage putting it mildly it would be nice to have some cheerful news from the targeted drug delivery space.

https://www.fiercepharma.com/pharma/enhertus-disruptive-her2-low-breast-cancer-nod-could-come-year-az-daiichi-ask-fda-ambitious

https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis